<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918839</url>
  </required_header>
  <id_info>
    <org_study_id>DMEDVINCI001</org_study_id>
    <secondary_id>DMEDVINCI001</secondary_id>
    <nct_id>NCT01918839</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Injection With VINCI Plus Hyaluronic Acid Filler</brief_title>
  <official_title>Clinical Study to Evaluate the Efficacy and Safety of Injection With VINCI Plus as Compared to Restylane-L in Correction of Nasolabial Fold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>D.med</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>D.med</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is intended to evaluate the efficacy and safety of injection with VINCI
      Plus as compared to Restylane-LÂ® in correction of nasolabial fold.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wrinkle Severity Rating Scale (WSRS) Evaluation</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Wrinkle Severity Rating Scale (WSRS) evaluation at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wrinkle Severity Rating Scale (WSRS) Evaluation</measure>
    <time_frame>At 2 weeks, 6 weeks</time_frame>
    <description>Wrinkle Severity Rating Scale (WSRS) Evaluation at 2 weeks, and 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) Evaluation</measure>
    <time_frame>At 2 weeks, 6 weeks and 12 weeks</time_frame>
    <description>Global Aesthetic Improvement Scale (GAIS) Evaluation at 2 weeks, 6 weeks and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pain assessment at each time point</measure>
    <time_frame>at injection and 15, 30, 45, and 60 min after injection</time_frame>
    <description>VAS pain assessment at each time point (at injection and 15, 30, 45, and 60 min after injection)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Nasolabial Fold Improvement</condition>
  <arm_group>
    <arm_group_label>VINCI Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One side has been treated with VINCI Plus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane-L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One side has been treated with Restylane-L</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VINCI Plus</intervention_name>
    <description>VINCI Plus 1ml injected into wrinkle treatment area</description>
    <arm_group_label>VINCI Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane-L</intervention_name>
    <description>Restylane-L injected into wrinkle treatment area</description>
    <arm_group_label>Restylane-L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the ages of 30-65, at the point of screening, wrinkles on both
             sides of treatment area (nasolabial fold) are in the 3rd or 4th level on the
             WSRS(Wrinkle Severity Rating Score)

          -  Surrounding soft tissue of wrinkles on both sides of nose and lips are sagging

          -  Wrinkles of both sides of nose and lips are visually symmetric

          -  Agrees to stop all other treatment of facial wrinkle improvement including dermatology
             treatment during clinical trial

          -  Able to understand and follow instructions and participate the entire period of the
             clinical trial

          -  Subject voluntarily agrees to participate in clinical trial and gives informed written
             consent

        Exclusion Criteria:

          -  At the point of screening, intradermal test results show skin irritation to medical
             devices of clinical trial

          -  Within 2 weeks before the date of screening, subject has taken antithrombotic (with
             the exception of low dose aspirin 100mg, up to 300mg/day) or non-steroidal
             anti-inflammatory medication

          -  Case where subject has abnormal liver function or blood coagulation, has to take
             antithrombotic medication (with the exception of low dose aspirin 100mg, up to
             300mg/day) during clinical trial

          -  Subject has used facial topical liniment (steroids, retinoids: excluding only
             medicines and cosmetics) within 4 weeks before date of screening or plans to continue
             using facial topical liniment during clinical trial

          -  Within 6 months before date of screening, subject has received anti-wrinkle or acne
             treatment

          -  Within 6 months before date of screening, subject has received facial
             microdermabrasion treatment, skin regeneration/rejuvenation treatment, plastic
             surgery, or cosmetic surgery (including Botox injections)

          -  Within 1 year before date of screening, subject has received CaHA (Calcium
             Hydroxyapatite) treatment on clinical trial medical device treatment area

          -  Subject has cured facial gel (Softform) or silicone implants inserted as permanent
             facial expansion

          -  Within 1 year before, subject had an illness that caused scarring or has scars on
             clinical trial medical device treatment area

          -  Subject has facial skin disease or skin wound infection that affects the clinical
             trial

          -  Weak immune system or suspect that the immune system is weak

          -  History of anaphylaxis or severe allergic complexity

          -  History of hypertrophic scar or keloid

          -  In the past, if there were adverse effects from EMLA Cream (if EMLA Cream was not
             used, the exclusion criteria for subjects applicable)

          -  History of hypersensitivity to Lidocaine

          -  Cardiovascular, digestive, respiratory, endocrine, central nervous system disorders
             that seems clinically significant or had a mental illness that had a significant
             impact on a previous clinical trial or currently has a mental illness

          -  Within 30 days before screening, subject participated in other clinical trials

          -  Female subjects of childbearing potential does not agree to a medically accepted
             method of contraception for the period of the clinical trial Medically acceptable
             methods of contraception: condoms; oral contraception continued for at least three
             months; or if intrauterine is used, installed a contraceptive device

          -  Pregnant women or nursing mothers

          -  In addition to the above, the test director or person in charge medically judges there
             are clinically significant findings that are improper for the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2013</study_first_posted>
  <last_update_submitted>August 1, 2014</last_update_submitted>
  <last_update_submitted_qc>August 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Investigational Device (VINCI Plus)</keyword>
  <keyword>Correction of nasolabial fold</keyword>
  <keyword>Wrinkle improvement</keyword>
  <keyword>Wrinkle correction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

